| 1 | 1 | | By: Guillen H.B. No. 4160 |
|---|
| 2 | 2 | | |
|---|
| 3 | 3 | | |
|---|
| 4 | 4 | | A BILL TO BE ENTITLED |
|---|
| 5 | 5 | | AN ACT |
|---|
| 6 | 6 | | relating to the creation of the Alzheimer's Research Collaborative |
|---|
| 7 | 7 | | of Texas. |
|---|
| 8 | 8 | | BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|---|
| 9 | 9 | | SECTION 1. Subchapter D, Chapter 102, Health and Safety |
|---|
| 10 | 10 | | Code, is amended by adding Section 102.157 to read as follows: |
|---|
| 11 | 11 | | Sec. 102.157. OVERSIGHT COMMITTEE FOR NEURODEGENERATIVE |
|---|
| 12 | 12 | | DISEASES. (a) In this section: |
|---|
| 13 | 13 | | (1) "Committee" means the Oversight Committee for |
|---|
| 14 | 14 | | Neurodegenerative Diseases. |
|---|
| 15 | 15 | | (2) "Nationally designated" means a designation from |
|---|
| 16 | 16 | | the National Institute on Aging. |
|---|
| 17 | 17 | | (3) "Research collaborative" means the Alzheimer's |
|---|
| 18 | 18 | | Research Collaborative of Texas. |
|---|
| 19 | 19 | | (b) The Oversight Committee for Neurodegenerative Diseases |
|---|
| 20 | 20 | | is the governing body of the Alzheimer's Research Collaborative of |
|---|
| 21 | 21 | | Texas. The committee is composed of the following eight members: |
|---|
| 22 | 22 | | (1) four members appointed by the lieutenant governor; |
|---|
| 23 | 23 | | and |
|---|
| 24 | 24 | | (2) four members appointed by the speaker of the house |
|---|
| 25 | 25 | | of representatives. |
|---|
| 26 | 26 | | (c) In making appointments to the committee, the lieutenant |
|---|
| 27 | 27 | | governor and the speaker of the house of representatives must each |
|---|
| 28 | 28 | | appoint: |
|---|
| 29 | 29 | | (1) three members who are physicians or scientists |
|---|
| 30 | 30 | | with extensive experience in the field of Alzheimer's disease and |
|---|
| 31 | 31 | | neurology; and |
|---|
| 32 | 32 | | (2) one member of the public. |
|---|
| 33 | 33 | | (d) From each group of appointees under Subsection (c)(1), |
|---|
| 34 | 34 | | one appointee must represent a nationally designated Alzheimer's |
|---|
| 35 | 35 | | Disease Research Center and shall serve as co-chair of the |
|---|
| 36 | 36 | | committee. |
|---|
| 37 | 37 | | (e) A member of the committee serves at the will of the |
|---|
| 38 | 38 | | official who appointed the member. |
|---|
| 39 | 39 | | (f) The research collaborative is established to support |
|---|
| 40 | 40 | | Alzheimer's disease research described by Subsection (h). The |
|---|
| 41 | 41 | | committee shall oversee the review processes and related procedures |
|---|
| 42 | 42 | | of the collaborative. |
|---|
| 43 | 43 | | (g) The committee shall establish standards and hire |
|---|
| 44 | 44 | | personnel as necessary to ensure the proper use of funds authorized |
|---|
| 45 | 45 | | for Alzheimer's disease research, facilities development, and |
|---|
| 46 | 46 | | caregiver resources consistent with the powers and duties described |
|---|
| 47 | 47 | | under Section 102.051. |
|---|
| 48 | 48 | | (h) The committee shall establish criteria for the research |
|---|
| 49 | 49 | | collaborative to support institutions of learning and advanced |
|---|
| 50 | 50 | | medical research facilities and collaborations in this state in all |
|---|
| 51 | 51 | | stages of finding the causes of Alzheimer's disease and other |
|---|
| 52 | 52 | | neurodegenerative diseases in humans and developing cures, from |
|---|
| 53 | 53 | | laboratory research to clinical trials, including programs to |
|---|
| 54 | 54 | | address the problem of access to advanced treatment for Alzheimer's |
|---|
| 55 | 55 | | disease. |
|---|
| 56 | 56 | | (i) The committee shall establish criteria for prioritizing |
|---|
| 57 | 57 | | its review of applications for grants to: |
|---|
| 58 | 58 | | (1) academic medical centers; |
|---|
| 59 | 59 | | (2) medical research facilities; and |
|---|
| 60 | 60 | | (3) collaborations with a nationally designated |
|---|
| 61 | 61 | | Alzheimer's Disease Research Center. |
|---|
| 62 | 62 | | SECTION 2. This Act takes effect September 1, 2023. |
|---|